The human endonuclease III enzyme is a relevant target to potentiate cisplatin cytotoxicity in Y‐box‐binding protein‐1 overexpressing tumor cells
Authors:
- 27 February 2008
- journal article
- Published by Wiley in Cancer Science
- Vol. 99 (4) , 762-769
Abstract
Y‐box‐binding protein‐1 (YB‐1) is a multifunctional protein involved in the regulation of transcription, translation, and mRNA splicing. In recent years, several laboratories have demonstrated that YB‐1 is directly involved in the cellular response to genotoxic stress. Importantly, YB‐1 is increased in tumor cell lines resistant to cisplatin, and the level of nuclear expression of YB‐1 is predictive of drug resistance and patient outcome in breast tumors, ovarian cancers, and synovial sarcomas. YB‐1 binds to several DNA repair enzymes in vitro including human endonuclease III (hNTH1). Human NTH1 is a bifunctional DNA glycosylase/apurinic/apyrimidinic lyase involved in base excision repair. In this study, we show that YB‐1 binds specifically to the auto‐inhibitory domain of hNTH1, providing a mechanism by which YB‐1 stimulates hNTH1 activity. Indeed, YB‐1 strongly stimulates in vitro the activity of hNTH1 toward DNA duplex probes containing oxidized bases, lesions prone to be present in cisplatin treated cells. We also observed an increase in YB‐1/hNTH1 complex formation in the mammary adenocarcinoma MCF7 cell line treated with UV light and cisplatin. Such an increase was not observed with mitomycin C or the topoisomerase I inhibitor camptothecin. Accordingly, antisense RNAs against either YB‐1 or hNTH1 increased cellular sensitivity to UV and cisplatin but not to mitomycin C. An antisense RNA against YB‐1 increased camptothecin sensitivity. In contrast, an antisense against hNTH1 did not. Finally, siRNA against hNTH1 re‐established cytotoxicity in otherwise cisplatin‐resistant YB‐1 overexpressing MCF7 cells. These data indicate that hNTH1 is a relevant target to potentiate cisplatin cytotoxicity in YB‐1 overexpressing tumor cells. (Cancer Sci 2008; 99: 762–769)Keywords
This publication has 26 references indexed in Scilit:
- Nuclear expression of Y‐box‐binding protein‐1 correlates with P‐glycoprotein and topoisomerase II alpha expression, and with poor prognosis in synovial sarcomaThe Journal of Pathology, 2003
- Increased nuclear localization of transcription factor YB-1 in acquired cisplatin-resistant ovarian cancerJournal of Cancer Research and Clinical Oncology, 2002
- Binding Capacity of Human YB-1 Protein for RNA Containing 8-OxoguanineBiochemistry, 2002
- Novel Translational Control through an Iron-Responsive Element by Interaction of Multifunctional Protein YB-1 and IRP2Molecular and Cellular Biology, 2002
- Y‐box factor YB‐1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI‐1International Journal of Cancer, 2001
- The RNA binding protein YB‐1 binds A/C‐rich exon enhancers and stimulates splicing of the CD44 alternative exon v4The EMBO Journal, 2001
- Role of single‐stranded DNA regions and Y‐box proteins in transcriptional regulation of viral and cellular genesThe FASEB Journal, 1998
- Direct Involvement of the Y-box Binding Protein YB-1 in Genotoxic Stress-induced Activation of the Human Multidrug Resistance 1 GeneJournal of Biological Chemistry, 1998
- Nuclear translocation of the Y‐box binding protein by ultraviolet irradiationFEBS Letters, 1997
- Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expressionNature Medicine, 1997